US FDA Finds Multiple Compliance Gaps at Dabur OTC Plant0

• A to Z, Food Hygiene, Food Laws, Health & Wellness, News
• May 30, 2026

Significant Update The US Food and Drug Administration (FDA) has raised serious compliance concerns at Dabur India‘s over-the-counter (OTC) manufacturing facility in Dadra and Nagar Haveli following an inspection conducted between January 12 and January 16, 2026. In a Form 483 inspection report, the regulator cited alleged documentation irregularities, data integrity concerns, questionable microbiology testing